Table 2.
Recruiting and active clinical trials (Clinicaltrials.gov, accession date: March 1, 2023)
|
Method
|
Interventions
|
NCT number
|
Phases
|
Title
|
Conditions
|
| Drug | ZED1227; Placebo | NCT05305599 | 2 | Different Doses of ZED1227 vs Placebo in NAFLD | NAFLD; Fibrosis |
| Tropifexor; Licogliflozin; Placebo | NCT04065841 | 2 | Efficacy, Safety, and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared with Placebo in Adult Patients with NASH and Liver Fibrosis | NASH; Liver fibrosis | |
| Tenofovir disoproxil Fumarate; PEG-Interferon alfa 2a | NCT03957629 | N/A | Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients with HBV-Related Liver Fibrosis | Hepatitis B; Fibrosis | |
| Sildenafil | NCT04908657 | 4 | Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation | Fibrosis | |
| Saroglitazar magnesium | NCT05011305 | 2 | Saroglitazar Magnesium for the Treatment of NASH with Fibrosis | NASH; Fibrosis | |
| Saroglitazar magnesium | NCT05045482 | 1 | Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease | Hepatic impairment; Cirrhosis | |
| Rivaroxaban apixaban | NCT04874428 | 1 | Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients with Liver Cirrhosis | Cirrhosis | |
| Resmetirom; Placebo | NCT05500222 | 3 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients with Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | NASH; Cirrhosis | |
| Rencofilstat; Placebo | NCT05402371 | 2 | A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects with NASH and Advanced Liver Fibrosis | NASH; Fibrosis, Liver NAFLD | |
| Placebo; Esomeprazole | NCT04448028 | 4 | Stop of Proton-pump Inhibitor Treatment in Patients with Liver Cirrhosis - a Double-blind, Placebo-controlled Trial | Liver cirrhosis | |
| PHIN-214 | NCT05490888 | 1 | Single Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Cirrhosis; Fibrosis; Hepatic ascites | |
| Placebo zibotentan + dapagliflozin | NCT05516498 | 2 | Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) | Cirrhosis | |
| L-ornithine; L-aspartate | NCT05737030 | 4 | Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome | Cirrhosis | |
| Hydronidone capsules; The placebo capsules | NCT05115942 | 3 | Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial | Liver fibrosis | |
| Growth hormone | NCT05253287 | 2/3 | Growth Hormone in Decompensated Liver Cirrhosis | Cirrhosis; Fibrosis | |
| Empagliflozin 10 MG; Placebo pills | NCT05147090 | 4 | Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B | NAFLD; Cirrhosis; Fibrosis | |
| Cotadutide; Placebo | NCT05364931 | 2/3 | A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis | Non-cirrhotic NASH with Fibrosis | |
| Candesartan; Ramipril | NCT03770936 | 3 | Effect of Some Drugs on Liver Fibrosis | Liver fibrosis | |
| Branched-chain amino acid; Placebo | NCT03633279 | 4 | Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients with Liver Cirrhosis-Child C | Liver cirrhosis | |
| BMS-986263; Placebo | NCT04267393 | 2 | Safety and Effectiveness of BMS-986263 in Adults with Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) | NASH | |
| AZD4831; Placebo | NCT05638737 | 2 | A Study in Participants with Non-cirrhotic NASH With Fibrosis | Non-cirrhotic NASH with fibrosis | |
| Atorvastatin; Placebo | NCT05028829 | 2 | Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk | Liver fibrosis; Cirrhosis | |
| Dietary supplement | Leucine enriched essential amino acid; Balanced amino acid supplement (BAA) | NCT03208868 | N/A | Leucine-Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis | Cirrhosis |
| Hydroxy methyl butyrate; Balanced Amino Acids | NCT05166499 | N/A | HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis | Cirrhosis | |
| Biological | Umbilical cord-derived mesenchymal stem cell comprehensive treatment | NCT03945487 | 2 | Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis | Decompensated liver cirrhosis |
| Mesenchymal stem cell | NCT03254758 | 1/2 | A Study of ADR-001 in Patients with Liver Cirrhosis | Decompensated liver cirrhosis | |
| Human umbilical cord-derived mesenchymal stem cells | NCT05227846 | 1 | Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1) | Decompensated cirrhosis | |
| Human umbilical cord-derived mesenchymal stem cell infusion | NCT05331872 | 1 | Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis | Liver cirrhosis | |
| Fecal microbiota transplantation; Placebo | NCT04932577 | 2/3 | Fecal Microbiota Transplantation for Liver Cirrhosis | Cirrhosis | |
| Cellgram-LC | NCT04689152 | 3 | Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients with Alcoholic Cirrhosis | Alcoholic cirrhosis | |
| Autologous BM MSC | NCT03626090 | 1/2 | Mesenchymal Stem Cell Therapy for Liver Cirrhosis | Cirrhosis | |
| Allogeneic umbilical cord mesenchymal stem cell | NCT04357600 | 1/2 | Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B | Cirrhosis | |
| Other | Weight loss | NCT05104541 | N/A | Impact of Weight Loss in Cirrhosis with Obesity and MAFLD | Liver cirrhosis |
| Lifestyle therapy bariatric surgery | NCT03472157 | N/A | A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients | Surgery; Obesity; NASH; Cirrhosis | |
| Indo mediterranean diet calorie restricted diet | NCT05073588 | N/A | Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children | NAFLD |
N/A: Not applicable; HCC: Hepatocellular carcinoma; NAFLD: Non-alcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.